Scientific Programme
12:30
Welcome
Session 1: From basic science to clinical application
Chair: Jan B. Vermorken (BE)
13:00
The gut microbiota and anticancer immunotherapy
Laurence Zitvogel (F)
13:25
The bidirectional communication between tumor cells and other components of the tumor microenvironment
Phil Sloan (UK)
13:50
Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this
Kirsten Lauber (DE)
14:15
DNA repair mechanisms as a new target in head and neck cancer
Kevin Harrington (UK)
14:40
Break and poster viewing
15:10
How to standardize molecular profiling programs for routine patient care
Ingeborg Tinhofer (DE)
15:35
Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer
Christophe Le Tourneau (F)
16:00
Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches
Ben O’Leary (UK)
16:25
Proffered paper session
Chaired by René Leemans
O01: Delay in the presentation of head and neck cancer in Scotland
following the COVID-19 pandemic
William Flynn (UK)
O02: Preclinical Implementation of a Steerable, Da Vinci Xi ®
Compatible CO2-Laser Fiber Carrier for Transoral Robotic Surgery (TORS):
a Cadaveric Feasibility Study
Jeroen Meulemans (BE)
O03: Dental status and weight loss in locally advanced oropharyngeal cancer
Doke Buurman (NL)
O04: Ultrasound-guided resection of tongue cancer
Klijs De Koning (NL)
17:30
19:00
News from the European Head & Neck Society (EHNS)
Wojciech Golusinski, President EHNS
19:15
Welcome reception
Session 2: Primary disease
Chair Piero Nicolai (I)
09:00
Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neck cancer
Brian O’Sullivan (CA)
09:25
From photon to proton: what’s in it for head and neck cancer patients?
Volker Budach (DE)
09:50
Lessons learned from RTOG 1016 and DE-ESCALaTE: what’s next?
Hisham Mehanna (UK)
10:15
Break and poster viewing
10:45
Treatment intensification in LA-SCCHN: what are the options and for who?
Jan Vermorken (BE)
11:10
Immune checkpoint inhibitors in the curative setting: preclinical and clinical data
Jean-Pascal Machiels (BE)
11:35
Carcinoma of unknown primary: diagnostics and the potential of transoral surgery
René Leemans (NL)
13:30
Lunch and sponsored symposium organized by MSD
13:30
Sponsored symposium organized by MSD
To view the programme of the sponsored symposium organized by MSD, click here.
Session 3: Recurrent and/or metastatic (R/M) SCCHN
Chair: Jan Vermorken (BE)
14:30
Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?
Petr Szturz (CH)
15:00
Patterns of response to immune oncology drugs: how relevant are they in SCCHN?
Amanda Psyrri (GR)
15:20
The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN
Daan Nevens (BE)
15:45
Break and poster viewing
16:15
Proffered paper session
Chaired by Jean-Pascal Machiels
O05: The added value of the comprehensive geriatric assessment
in the choice of treatment strategy for locally advanced head and
neck cancer patients
Paolo Bossi (IT)
O06: Incorporating immune response into TNM staging of early oral tongue cancer
Alhadi Almangush (FI)
O07: Image-based analysis of skeletal muscle mass predicts
cisplatin dose-limiting toxicity in patients with locally advanced
head and neck cancer
Remco de Bree (NL)
O08: Feasibility, SAR distribution and clinical outcome upon re-irradiation
and deep hyperthermia using the Hypercollar3D in head and neck
cancer patients
Michiel Kroesen (NL)
17:15
News from EORTC-HNCG
Jean-Pascal Machiels
17:30
Keynote lecture: Real world evidence in head and neck cancer
Anil D’Cruz (UICC president)
Session 4: Special topics
Chair: Brian O’Sullivan (CA)
09:00
Pathology driven treatment of skull base tumors
Piero Nicolai (I)
09:25
Modern day reconstruction of facial bones
Sat Parmar (UK)
09:50
Targeting molecular/minimal residual disease using novel technologies and clinical trials design
Lillian Siu (CA)
10:15
Break
10:45
New developments in surgery for malignant salivary gland tumors
Jeroen Meulemans (BE)
11:10
New systemic therapies in salivary gland cancer
Athanassios Argiris (GR)
11:35
Exercise and nutrition interventions in head and neck cancer
Paolo Bossi (I)
12:00
Telehealth intervention in head and neck cancer patients: a promise?
Irma Verdonck-de Leeuw (NL)
12:25
General discussion
13:00
Adjourn